Login to Your Account



Alkermes Selects Cephalon As Vivitrex Partner In $480M Deal

By Karen Pihl-Carey


Monday, June 27, 2005
A little more than two months after filing for approval of Vivitrex, Alkermes Inc. partnered the alcohol-dependence drug with Cephalon Inc. in a 50-50 profit-sharing deal worth an additional $480 million in up-front and milestone payments. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription